Design and Characterization of 4D-710, an Aerosolized Gene Therapy for Cystic Fibrosis Lung Disease
Melissa A. Calton, Roxanne H Croze, Theodore H Sullivan, Sara Collins, Sarah Tucker, Kevin J. Whittlesey, Daniel Kim, Julie A Nye, Ghezal Beliakoff, Melissa Quezada, Christian Burns, Chris Schmitt, Austin Klein, Vicky Jia, Laura Kovacs, Domokos Lauko, Kathryn E. Yoh, Kien Nguyen, Katherine Barglow, Johnny Gonzales, Devi Khoday, Thomas G. Mason, Kathy Delaria, Keenan Bashour, Melissa A. Kotterman, David V. Schaffer, An Song, Peter Francis, Jennifer L. Taylor‐Cousar, David H. Kirn
Abstract
Abstract Cystic fibrosis (CF) is an autosomal recessive disease caused by variants in the gene encoding the CF transmembrane conductance regulator (CFTR) protein. Delivery of a functional CFTR transgene to airway epithelial cells (AEC) offers the potential to provide durable restoration of normal CFTR function. Adeno-associated virus (AAV) vectors are the leading platform for the delivery of in vivo gene therapy; however, wild-type AAV vectors exhibit a limited capacity to transduce airway cells and evade pre-existing human neutralizing antibodies (NAb). We therefore employed a directed evolution platform to invent a novel AAV capsid (A101) with the capacity to efficiently transduce AECs, including in the presence of NAbs, following aerosolized administration to nonhuman primates (NHP). We then engineered 4D-710, a gene therapy comprising the A101 vector and a CFTR transgene with a partial deletion in the regulatory domain (CFTRΔR) to facilitate vector packaging. 4D-710 exhibited efficient transduction of human bronchial epithelial (HBE) cell air–liquid interface (ALI) cultures in vitro and robust functional activity in CF HBE ALI cultures. Aerosolized administration of 4D-710 to NHPs was well tolerated and resulted in dose-dependent transgene expression and increased CFTR protein in diverse AEC types compared to vehicle controls. No significant differences in CFTRΔR mRNA levels were observed in lung samples from NHPs with pre-existing serum anti-capsid NAbs compared to NAb-negative NHPs. These findings demonstrate the tolerability and feasibility of A101-mediated transgene delivery and expression in primate airways. A clinical trial evaluating aerosol delivery of 4D-710 in adults with CF (NCT05248230) is underway.